For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Immunovant Inc (NASDAQ: IMVT) closed the day trading at $23.6 down -2.44% from the previous closing price of $24.19. In other words, the price has decreased by -$2.44 from its previous closing price. On the day, 1.47 million shares were traded. IMVT stock price reached its highest trading level at $24.295 during the session, while it also had its lowest trading level at $23.37.
Ratios:
For a better understanding of IMVT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.32 and its Current Ratio is at 12.32. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Hold rating and assigned the stock a target price of $16.
On March 03, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $20.Jefferies initiated its Hold rating on March 03, 2025, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 22 ’25 when Geffner Michael sold 2,595 shares for $19.03 per share. The transaction valued at 49,383 led to the insider holds 217,958 shares of the business.
Stout Jay S sold 2,520 shares of IMVT for $47,956 on Oct 22 ’25. The Chief Technology Officer now owns 200,814 shares after completing the transaction at $19.03 per share. On Oct 08 ’25, another insider, Geffner Michael, who serves as the Chief Medical Officer of the company, sold 1,272 shares for $16.30 each. As a result, the insider received 20,734 and left with 220,553 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4113877760 and an Enterprise Value of 3514965504.
Stock Price History:
The Beta on a monthly basis for IMVT is 0.56, which has changed by -0.1917808 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, IMVT has reached a high of $32.10, while it has fallen to a 52-week low of $12.72. The 50-Day Moving Average of the stock is 34.11%, while the 200-Day Moving Average is calculated to be 37.08%.
Shares Statistics:
Over the past 3-months, IMVT traded about 1.71M shares per day on average, while over the past 10 days, IMVT traded about 2281020 shares per day. A total of 171.07M shares are outstanding, with a floating share count of 70.60M. Insiders hold about 59.50% of the company’s shares, while institutions hold 55.42% stake in the company. Shares short for IMVT as of 1760486400 were 17009989 with a Short Ratio of 9.95, compared to 1757894400 on 16147300. Therefore, it implies a Short% of Shares Outstanding of 17009989 and a Short% of Float of 28.449999999999996.
Earnings Estimates
A comprehensive evaluation of Immunovant Inc (IMVT) is underway, with the input of 13.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.6 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.33 and -$3.32 for the fiscal current year, implying an average EPS of -$2.91. EPS for the following year is -$3.0, with 11.0 analysts recommending between -$1.96 and -$3.98.
